文献速递白血病造血干细胞移植与细胞治疗

共转导CD19/CD22靶向CAR T细胞预防B细胞急性淋巴细胞白血病CAR T细胞治疗后抗原阴性复发

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
PubMed 文献 · Blood · 2024-01-01

研究采用慢病毒共转导生成同时靶向CD19和CD22的CAR T细胞产品(AUTO1与新型CD22 CAR联合),治疗12例晚期B细胞急性淋巴细胞白血病患者,其中三分之一既往经获批CAR治疗失败。输注后2个月10例(83%)达微小残留病阴性完全缓解,中位随访8.7个月无抗原阴性逃逸复发,6个月和12个月总生存率均为75%。

要点

  • 12例晚期B细胞急性淋巴细胞白血病患者接受CD19/CD22共转导CAR T细胞治疗,毒性类似单用AUTO1,无重度细胞因子释放综合征。
  • 输注后2个月10例(83%)达微小残留病阴性完全缓解。
  • 中位随访8.7个月无抗原阴性逃逸复发,6个月和12个月总生存率均为75%。

核心结论

  • 共转导双靶向策略可能预防CAR T细胞治疗后的抗原阴性复发。

研究设计与样本

  • CARPALL研究(NCT02443831),采用慢病毒共转导编码AUTO1(快速解离率CD19 CAR)与新型CD22 CAR的载体生成CAR T细胞产品,治疗12例晚期B细胞急性淋巴细胞白血病患者。

主要发现

  • 12例中10例(83%)在输注后2个月达微小残留病阴性完全缓解。
  • 10例缓解者中5例出现微小残留病再现(n=2)或复发(n=3),均为CD19和CD22表达且伴CAR T细胞持久性丧失。
  • 中位随访8.7个月,无抗原阴性逃逸所致复发。
  • 6个月和12个月总生存率均为75%(95%CI 41%-91%)。
  • 6个月和12个月无事件生存率分别为75%(95%CI 41%-91%)和60%(95%CI 23%-84%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-negative relapse is a leading cause of treatment failure after chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia. We investigated a CAR T-cell product targeting CD19 and CD22 generated by lentiviral cotransduction with vectors encoding our previously described fast-off rate CD19 CAR (AUTO1) combined with a novel CD22 CAR capable of effective signaling at low antigen density. Twelve patients with advanced B-cell acute lymphoblastic leukemia were treated (CARPALL [Immunotherapy with CD19/22 CAR Redirected T Cells for High Risk/Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia] study, NCT02443831), a third of whom had failed prior licensed CAR therapy. Toxicity was similar to that of AUTO1 alone, with no cases of severe cytokine release syndrome. Of 12 patients, 10 (83%) achieved a measurable residual disease (MRD)-negative complete remission at 2 months after infusion. Of 10 responding patients, 5 had emergence of MRD (n = 2) or relapse (n = 3) with CD19- and CD22-expressing disease associated with loss of CAR T-cell persistence. With a median follow-up of 8.7 months, there were no cases of relapse due to antigen-negative escape. Overall survival was 75% (95% confidence interval [CI], 41%-91%) at 6 and 12 months. The 6- and 12-month event-free survival rates were 75% (95% CI, 41%-91%) and 60% (95% CI, 23%-84%), respectively. These data suggest dual targeting with cotransduction may prevent antigen-negative relapse after CAR T-cell therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ghorashian S, Lucchini G, Richardson R, et al. CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood. 2024. PMID: 37647647. doi:10.1182/blood.2023020621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。